Borelli, Alexia https://orcid.org/0000-0003-2611-7541
Santamaria, Jérémy C. https://orcid.org/0000-0001-7613-3668
Zamit, Cloé https://orcid.org/0009-0001-7038-6805
Apert, Cécile
Chevallier, Jessica https://orcid.org/0000-0001-5109-5079
Pierre, Philippe https://orcid.org/0000-0003-0863-8255
Argüello, Rafael J. https://orcid.org/0000-0001-9785-3883
Spinelli, Lionel
Irla, Magali https://orcid.org/0000-0001-8803-9708
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-22-CE18-0045-01)
Fondation ARC pour la Recherche sur le Cancer (PJA20171206491)
Inserm CoPoC - proof of concept
Article History
Received: 26 September 2023
Accepted: 31 July 2024
First Online: 14 August 2024
Competing interests
: The authors declare the existence of a financial/non financial competing interest. M.I. holds a patent related to Treg genetically modified for the lymphotoxin alpha gene (PCT/EP2020/063346; WO2020229546A1). There are restrictions to the commercial use of SCENITH<sup>TM</sup> due to pending patent application (PCT/EP2020/060486;WO2020212362A1 to R.J.A.). All other authors declare no competing interests.